Seek Labs Expands Oncology Research for Sequence Ablation Therapeutics with Up to $3 Million in Foundation Support
Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis SnyderSALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Seek Labs, a Salt Lake City Tech Bio company developing programmable CRISPR-based medicines, today announced an agreement with the Two2Ten Foundation providing up to $3 million to support the continued expansion of its Sequence Ablation Therapeutics (SAT) platform into oncology. The f Seek Labs, a Salt Lake City Tech Bio company developing programmable CRISPR-based medicines, has announced an agreement with the Two2Ten Foundation to provide up to $3 million to support the expansion of its Sequence Ablation Therapeutics (SAT) platform into oncology. The funding will support preclinical research applying Seek Labs' programmable therapeutic approach to cancer, with the aim of creating new options for patients underserved by existing treatments. The collaboration reflects a shared belief that existing treatments leave too many patients without effective options and that advancing cancer care requires investment in new therapeutic approaches. Heidi Snyder, President of the Two 2Ten Foundation, whose husband, Travis Snyder, passed away from acute myeloid leukemia, emphasized that the next generation of cancer treatments will come from people willing to think differently.
Yayınlanan : Dün ile Seek Labs içinde Health Tech Science
Two2Ten Foundation supports the continued development of Seek Labs' Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis Snyder
SALT LAKE CITY, Oct. 26, 2026 (GL... [2679 symbols]
